| 产品名称 | 圣草酚CAS: 552-58-9原料药研发供应中间体 |
|---|---|
| 公司名称 | 南京辰瑞晟生物医药科技有限公司 |
| 价格 | .00/件 |
| 规格参数 | 品牌:CRS 型号:CMO 产地:国产 |
| 公司地址 | 南京市雨花台区安德门大街57号楚翘城5幢503-008室（注册地址） |
| 联系电话 | 0571-87428035 15360676961 |
| 中文名 | 圣草酚 |
| 英文名 | (S)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-4-benzopyrone |
| 别名 | 圣草酚 毛纲草酚 (S)-圣草酚 圣草酚(标准品) 毛纲草酚对照品, 圣草酚, 来源于柠檬 3',4',5,7-四羥二氫黃酮 (S)-2-(3,4-二羟基苯基)-2,3-二氢-5,7-二羟基-4-香豆素 |
| 英文别名 | Eriodictyol ERIODICTYOL ERIODICTYOL(SH) 5,7,3',4'-TETRAHYDROXYFLAVANONE 3',4',5,7-tetrahydroxyflavanone 3',4',5,7-TETRAHYDROXYFLAVANONE (S)-3',4',5,7-TETRAHYDROXYFLAVANONE (2S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4H-chromen-4-one (S)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-4-benzopyrone 2-[3,4-DIHYDROXYPHENYL]2,3-DIHYDRO-5,7-DIHYDROXY-4H-1BENZOPYRAN-4-ONE 4H-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy- |
| CAS | 552-58-9 |
| EINECS | 209-016-4 |
| 化学式 | C15H12O6 |
| 分子量 | 288.25 |
| InChI | InChI=1/C15H12O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-5,13,16-19H,6H2 |
| InChIKey | SBHXYTNGIZCORC-ZDUSSCGKSA-N |
| 密度 | 1.586±0.06 g/cm3(Predicted) |
| 熔点 | 270°C |
| 沸点 | 625.2±55.0 °C(Predicted) |
| 闪点 | 241.9°C |
| 水溶性 | 70mg/L(20 C) |
| 蒸汽压 | 3.19E-16mmHg at 25°C |
| JECFA Number | 2172 |
| 溶解度 | DMSO (Slightly), Methanol (Very Slightly) |
| 折射率 | 1.724 |
| 酸度系数 | 7.49±0.40(Predicted) |
| 存储条件 | 2-8°C |
| 稳定性 | Hygroscopic |
| 外观 | neat |
| 颜色 | White to Pale Beige |
| BRN | 5104930 |
| 物化性质 | 易溶于甲醇,略微溶于沸水、热乙醇、yimi及冰醋酸,溶于稀碱。 来源于田麻科植物圣草 |
| MDL号 | MFCD00017312 |
| 体外研究 | Eriodictyol is a flavonoid isolated from the Chinese herb, with antioxidant and anti-inflammatory activity. Eriodictyol (20, 40, 80 μM) protects primary cultured cortical neurons against Aβ 25-35 -induced cytotoxicity and cell apoptosis via the Nrf2/ARE pathway. Eriodictyol (80 μM) induces nuclear expression of Nrf2 and the expression of ARE-regulated genes in primary cultured cortical neurons. |
| 体内研究 | Eriodictyol shows protective effect against LPS-induced acute lung injury (ALI). Eriodictyol (30 mg/kg, p.o.) decreases the production of inflammatory cytokines, elevates survival rate, and decreases oxidative stress levels in LPS-induced ALI mice. Eriodictyol inhibits MPO activity and inflammatory neutrophil accumulation in the lung tissues. Eriodictyol treatment also enhances Trx1 expression by upregulating the Nrf2 expression in lung tissues. |